Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform

On October 14, 2019 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, reported having received a communication from the European Patent Office (EPO) informing the Company of its intent to grant a new patent strengthening the European protection of compounds sourced from its platON platform (Press release, Onxeo, OCT 14, 2019, View Source [SID1234540989]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This new patent strengthens the patent portfolio around AsiDNA, the Company’s first-in-class DNA Damage Response (DDR) inhibitor. It protects AsiDNA and related compounds, as such and for their therapeutic use, in particular for the treatment of cancers, alone or in combination with other agents such as radiotherapy, chemotherapy or other tumor DNA-damaging agents.

"This intent-to-grant, which was obtained very quickly after filing the application, illustrates the value of our platON platform through its ability to generate new patentable compounds and confirms the highly innovative nature of the products resulting from our technology to block the signaling pathways involved in the repair of tumor DNA," said Françoise Bono, Chief Scientific Officer of Onxeo.

This patent will provide a term of protection valid until mid-2031, which could be further extended until 2036 via the supplementary protection certificate (SPC) system. It completes the already robust set of 9 patent families securing the protection of AsiDNA and its related compounds.